Claritev (NYSE:CTEV) EVP Michael Kim Acquires 15,000 Shares

Claritev (NYSE:CTEV) EVP Michael Kim purchased 15,000 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was acquired at an average price of $16.50 per share, for a total transaction of $247,500.00. Following the purchase, the executive vice president owned 182,878 shares in the company, valued at approximately $3,017,487. The trade was a 8.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Michael Kim also recently made the following trade(s):

• On Friday, February 27th, Michael Kim purchased 30,000 shares of Claritev stock. The shares were acquired at an average cost of $14.30 per share, with a total value of $429,000.00.

Claritev Price Performance

Shares of CTEV stock traded up $1.64 on Monday, hitting $18.53. 21,815 shares of the company’s stock were exchanged, compared to its average volume of 226,946. The company has a 50 day moving average of $23.93 and a 200 day moving average of $42.93. The stock has a market cap of $305.93 million, a P/E ratio of -1.07 and a beta of 0.61. Claritev has a 12 month low of $12.04 and a 12 month high of $74.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers acquired a new stake in Claritev in the third quarter worth $567,000. JPMorgan Chase & Co. bought a new position in shares of Claritev during the 3rd quarter worth about $1,245,000. Vanguard Group Inc. bought a new position in shares of Claritev during the 3rd quarter worth about $27,483,000. Citigroup Inc. acquired a new stake in shares of Claritev in the 3rd quarter valued at about $2,025,000. Finally, Ameritas Investment Partners Inc. acquired a new stake in shares of Claritev in the 3rd quarter valued at about $42,000. 87.15% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Claritev in a report on Monday, December 29th. Wells Fargo & Company set a $30.00 price target on Claritev and gave the stock an “equal weight” rating in a report on Tuesday, February 24th. UBS Group reaffirmed a “buy” rating on shares of Claritev in a report on Tuesday, February 24th. Guggenheim reaffirmed a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Finally, Citigroup dropped their price objective on Claritev from $63.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $29.67.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.